Search This Blog

Tuesday, December 27, 2022

Nanobiotix Starts Phase 3 Pivotal Trial in Head and Neck Cancer

 

  • Patients randomized in all planned major regions for pivotal phase 3 NANORAY-312 study with the United States added to Europe and Asia

  • NANORAY-312 now has sites activated across 80 sites globally

  • Phase 3 futility analysis expected in 2H 2023, with interim Phase 3 data expected in 2H 2024

Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)